In vitro synergism of ciprofloxacin and cefotaxime against nalidixic acid-resistant Salmonella enterica serotypes paratyphi A and paratyphi B

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 9, 2010, Pages 3696-3701

  Neupane, Ganesh Prasad ^a   Kim, Dong Min ^a,b   Kim, Sung Hun ^c   Lee, Bok Kwon ^c  

^a Chosun University   (South Korea)

^b Chosun University College of Medicine   (South Korea)

^c Korea National Institute of Health   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; CIPROFLOXACIN; NALIDIXIC ACID; RIFAMPICIN;

ARTICLE; BACTERIAL COUNT; BACTERIAL GENE; CODON; GENE MUTATION; IN VITRO STUDY; PARATYPHOID FEVER; PRIORITY JOURNAL; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B;

BACTERIAL PROTEINS; CEFOTAXIME; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MUTATION; NALIDIXIC ACID; SALMONELLA PARATYPHI A;

EID: 77956129465     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00988-09     Document Type: Article

References (31)

1. Adachi, T., H. Sagara, K. Hirose, and H. Watanabe. 2005. Fluoroquinolone resistant Salmonella Paratyphi A. Emerg. Infect. Dis. 11:172-173.
2. Ausubel, F. M., R. Brent, and R. E. Kingstone (ed.). 1996. Current protocols in molecular biology. John Wiley & Sons, New York, NY.
3. Chapman, J. S., and N. H. Georgopapadakou. 1988. Routes of quinolone permeation in Escherichia coli. Antimicrob. Agents Chemother. 32:438-442.
4. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing; 18th informational supplement, vol. 28, no 1. Document no. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Drusano, G. L., W. Liu, D. L. Brown, L. B. Rice, and A. Louie. 2009. Impact of short course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J. Infect. Dis. 199:219-226.
6. Eaves, D. J., L. Randall, D. T. Gray, A. Buckley, M. J. Woodward, A. P. Wgite, and L. J. V. Piddock. 2004. Prevalence of mutations within the quinolone resistance determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone resistant Salmonella enterica. Antimicrob. Agents Chemother. 48:4012-4015.
7. Eltringham, I. J., N. Thalange, D. Ireland, H. Issler, and A. Teall. 1997. A relapse of paratyphoid fever after treatment with ciprofloxacin in a child with congential biliary atresia. Acta Paediatr. 86:547-548.
8. Gall, S. L., L. Desbordes, P. Gracieux, S. Saffroy. L. Bousarghin, M. Bonnaure- Mallet, and A. Jolivet-Gougeon. 2009. Distribution of mutation frequencies among Salmonella enterica isolates from animal and human sources and genetic characterization of a Salmonella Heidelberg hypermutator. Vet. Microbiol. 137:306-312.
9. Giraud, E., A. Cloeckaert, D. Kerboeuf, and E. Chaslus-Dancla. 2000. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enteric serovar Typhimurium. Antimicrob. Agents Chemother. 44:1223-1228.
10. Hirose, K., A. Hashimoto, K. Tamura, Y. Kawamura, T. Ezaki, H. Sagara, and H. Watanabe. 2002. DNA sequence analysis of DNA gyrase and DNA topoisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A. Antimicrob. Agents Chemother. 46:3249-3252.
11. Hopkins, K. L., R. H. Davies, and E. J. Threlfall. 2005. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int. J. Antimicrob. Agents 25:358-373.
12. Jacoby, G. A. 2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41:S120-S126.
13. Kariuki, S., G. Revathi, J. Muyodi, J. Mwituria, A. Munyalo, S. Mirza, and C. A. Hart. 2004. Characterization of multidrug-resistant typhoid outbreaks in Kenya. J. Clin. Microbiol. 42:1477-1482.
14. Kim, D. M., C. I. Kang. C. S. Lee, H. B. Kim, E. C. Kim, N. J. Kim, M. D. Oh, and K. W. Choe. 2006. Treatment failure due to emergence of resistance to carbapenem during therapy for Shewanella algae bacteremia. J. Clin. Microbiol. 44:1172-1174.
15. Kim, D. M., G. P. Neupane, S. J. Jang, S. H. Kim, and B. K. Lee. 2010. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against nalidixic acid resistant Salmonella enterica serotype Typhi. Int. J. Antimicrob. Agents. 36:155-158.
16. Kim, D. M., N. R. Yun, and J. H. Chung. 2008. Time kill studies of antibiotics against a nalidixic acid resistant Salmonella enterica serotype Typhi. Infect. Chemother. 40:207-211.
17. Kim, D. M., Y. Lym, S. J. Jang, H. Han, Y. G. Kim, C. H. Chung, and S. P. Hong. 2005. In vitro efficacy of the combination of ciprofloxacin and cefotaxime against Vibrio vulnificus. Antimicrob. Agents Chemother. 49:3489-3491.
18. Lindgren, M. M., P. Kotilainen, P. Huovinen, S. Hurme, S. Lukinmaa, M. A. Webber, L. J. Piddock, A. Siitonen, and A. J. Hakanen. 2009. Reduced fluoroquinolone susceptibility in Salmonella enterica isolates from travelers, Finland. Emerg. Infect. Dis. 15:809-812.
19. Nair, S., M. Unnikrishnan, K. Turner, S. C. Parija, C. Churcher, J. Wain, and N. Harish. 2006. Molecular analysis of fluoroquinolone resistant Salmonella Paratyphi A isolate, India. Emerg. Infect. Dis. 12:489-491.
20. Ochiai, R. L., X. Y. Wang, L. V. Seidlein, J. Yang, Z. A. Bhutta, S. K. Bhattacharya, M. Agtini, J. L. Deen, J. Wain, D. R. Kim, M. Ali, C. J. Acosta, L. Jodar, and J. D. Clemens. 2005. Salmonella Paratyphi A rates, Asia. Emerg. Infect. Dis. 11:1764-1766.
21. Pandit, A., A. Arjyal, J. N. Day, B. Paudyal, S. Dangol, M. D. Zimmerman, B. Yadav, K. Stepniewska, J. I. Campbell, C. Dolecek, J. J. Farrar, and B. Basnyat. 2007. An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever. PLoS One 2:e542.
22. Parry, C., J. Wain, N. T. Chinh, H. Vinh, and J. J. Farrar. 1998. Quinolone-resistant Salmonella Typhi in Vietnam. Lancet 351:1289.
23. Parry, C. M., T. T. Hien, G. Dougan, N. J. White, and J. J. Farrar. 2002. Typhoid fever. N. Engl. J. Med. 347:1770-1782.
24. Parry, C. M., V. A. Ho, T. Phuong le, P. V. Bay, M. N. Lanh, T. Tung le, N. T. Tham, J. Wain, T. T. Hien, and J. J. Farrar. 2007. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob. Agents Chemother. 51:819-825.
25. Pokhrel, B. M., J. Koirala, R. K. Dahal, S. K. Mishra, P. K. Khadga, and N. R. Tuladhar. 2006. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)-producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int. J. Infect. Dis. 10:434-438.
26. Rupali, P., O. C. Abraham, M. V. Jesudason, T. J. John, A. Zachariah, S. Sivaram, and D. Mathai. 2004. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn. Microbiol. Infect. Dis. 49:1-3.
27. Saha, S. K., S. Y. Talukder, M. Islam, and S. Saha. 1999. A highly ceftriaxone- resistant Salmonella Typhi in Bangladesh. Pediatr. Infect. Dis. J. 18:387.
28. Shirakawa, T., B. Acharya, S. Kinoshita, S. Kumagai, A. Gotoh, and M. Kawabata. 2006. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated in Kathmandu, Nepal, in 2003. Diagn. Microbiol. Infect. Dis. 54:299-303.
29. Thong, K. L., S. Nair, R. Chaudhry, P. Seth, A. Kapil, D. Kumar, H. Kapoor, S. Puthucheary, and T. Pang. 1998. Molecular analysis of Salmonella Paratyphi A from an outbreak in New Delhi, India. Emerg. Infect. Dis. 4:507-508.
30. Threlfall, E. J., and L. R. Ward. 2001. Decreased susceptibility to ciprofloxacin in Salmonella enterica serotype Typhi in the United Kingdom. Emerg. Infect. Dis. 7:448-450.
31. Vidaillac C., S. N. Leonard, H. S. Sader, R. N. Jones, and M. J. Rybak. 2009. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant Gram-negative pathogens, including β-lactamase- producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:2360-2366.